Peptide news
Curated weekly from FDA notices, manufacturer press releases, peer-reviewed studies, and trusted outlets. Direct source links on every item. Practical takeaways for users, not academic abstracts.
- Regulatorystatnews.com
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Telehealth providers are prescribing GLP-1 drugs off label for addiction before FDA approval for that use. If you're considering this treatment, ask your prescriber what evidence supports it and how they'll monitor benefits and side effects.
Read source → - Regulatorystatnews.com
STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
The headline reports that Belgium is refusing Mounjaro coverage, but the available text does not specify which patients or uses are affected. If you use Mounjaro in Belgium, check with your insurer whether your next refill is covered and what you would need to pay.
Read source → - Regulatorynews.google.com
What to Know About the GLP-1 Pill Orforglipron
This is an oral GLP-1 access or trial signal around orforglipron, Lilly's non injectable GLP-1. Watch approval status, coverage rules, and full trial data before treating it like a replacement for injectable GLP-1s.
Read source → - Regulatorynews.google.com
Bootleg Retatrutide Deaths? PMOS and Dementia; Weight-Loss Drug to Be Discontinued
The headline raises questions about possible deaths involving bootleg retatrutide and mentions a weight loss drug discontinuation, but it provides no details confirming a link or naming the discontinued drug. If you use retatrutide, ask your prescriber or pharmacist to verify your product’s source before your next dose.
Read source → - Trialslilly.gcs-web.com
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
Lilly’s exploratory Phase 3b analysis found changes in more psoriasis related and metabolic biomarkers with Taltz plus Zepbound (tirzepatide) than with Taltz alone, as early as Week 12. The study involved adults with psoriasis and obesity or qualifying overweight, but biomarker changes alone do not establish better symptom control. If you have psoriasis and use tirzepatide, look for clinical benefit and safety results before treating these findings as a reason to change your treatment.
Read source → - Regulatorynews.google.com
Trevogrumab Curbs Muscle Loss on GLP-1, Aids Regain After
Trevogrumab may help limit muscle loss during GLP-1 treatment and support muscle regain afterward. If you use a GLP-1, look for full study results on muscle strength and safety before considering trevogrumab for muscle preservation.
Read source → - Safetylilly.gcs-web.com
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
In a post hoc analysis of ATTAIN-1, Lilly’s oral GLP-1 drug Foundayo (orforglipron) at 17.2 mg was associated with 57% lower predicted risk of type 2 diabetes and 18% lower predicted cardiovascular disease risk over 10 years versus placebo. These are modeled estimates, not demonstrated reductions in actual diagnoses or cardiovascular events. If you’re considering orforglipron, ask your prescriber how these estimates apply to your own risk.
Read source → - Safetynews.google.com
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Lilly reports that its oral GLP-1, Foundayo (orforglipron), was associated with lower predicted long term risk of type 2 diabetes and cardiovascular disease. If you're considering it, watch for evidence of fewer actual diabetes diagnoses and cardiovascular events, since lower predicted risk does not establish those benefits.
Read source → - Trialsnews.google.com
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial
Regeneron’s weight loss drug halved muscle loss when combined with Novo’s semaglutide in a trial. If you use semaglutide, watch for the full results to see whether that muscle preservation also translated into better strength or physical function.
Read source → - Regulatorylilly.gcs-web.com
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Lilly reports that Foundayo (orforglipron), an oral GLP-1 drug, improved A1C and weight while meeting its cardiovascular safety goal versus insulin glargine in adults with type 2 diabetes and elevated cardiovascular risk. The reported 16% lower risk on the main cardiovascular event measure does not itself prove better heart protection, because the primary goal was to show comparable safety. If you’re considering orforglipron, ask your prescriber how these results apply to your heart risk and current diabetes treatment.
Read source → - Regulatorynews.google.com
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Lilly reports that Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reductions than oral semaglutide 25 mg in adults with type 2 diabetes, based on an indirect comparison. If you’re weighing these options, ask your prescriber how the underlying trials differ before using this result to guide a treatment change.
Read source → - Regulatorynews.google.com
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes
This study indirectly compares tirzepatide and semaglutide for effectiveness and safety in people with obesity or overweight who do not have type 2 diabetes. If you're choosing between them, review the full results with your prescriber before switching, because the title alone does not establish which works better or is safer.
Read source →
Pepdex aggregates research news from primary sources only, FDA Federal Register notices, manufacturer investor releases, peer-reviewed studies on PubMed / NEJM / Lancet, and trusted outlets (BioPharma Dive, STAT, AJMC, university research pages). We summarize in plain English; you click the source link to verify. No vendor sponsorship.